

Janssen-Organized Dermatology Webcast

# Highlights of EADV 2019

## Faculty

**Alexander Egeberg (Scientific Committee)**

**Jo Lambert (Scientific Committee)**

**Brian Kirby**

**Tuesday 22 October 2019**

**Live webcast: 17:30–18:30 (CET)**

This webcast will provide a **summary of important developments** in the field of inflammatory skin diseases that were **presented at EADV 2019**. The main focus will be on psoriasis, but highlights of other inflammatory skin diseases such as atopic dermatitis will also be covered. The speakers will **discuss the most interesting posters and oral presentations** and interpret the data in the wider context of inflammatory skin disease. The audience worldwide will have the opportunity to interact with the faculty during the interactive segments of the programme.

We hope you can join us during this live, interactive session. If you are unable to attend the live broadcast, you will be able to watch the on-demand version once it is available.

Registration is required.





Please scan the QR code to register for the Janssen-organized dermatology webcast entitled: **Highlights of EADV 2019**

## Learning objectives

After this meeting, participants should be able to:

- Recognize the clinical implications of the pathophysiology of inflammatory skin diseases and their comorbidities
- Analyse the safety and efficacy clinical data, in addition to real-world data from registries and other sources
- Identify special populations in inflammatory skin diseases and the optimal approach to the management of these patients

## Programme

17:30–17:35	<b>Welcome and introduction</b>
17:35–17:40	<b>Getting to know the audience</b>
17:40–18:00	<b>Highlights of EADV 2019</b>
18:00–18:15	<b>Additional Q&amp;A based on audience-submitted questions</b>
18:15–18:25	<b>A look into the future</b>
18:25–18:30	<b>Final words and summary</b>

With the support of Janssen Pharmaceutical Companies  
of Johnson & Johnson in EMEA

Janssen Pharmaceutica NV  
Turnhoutseweg 30  
B-2340 Beerse, Belgium

Date of preparation: April 2019  
EM-09162



PHARMACEUTICAL COMPANIES OF Johnson & Johnson